عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Banksy Unveils New Rhino Art in London

A person takes a photo of a new artwork by the British artist Banksy in Charlton, London, Britain, August 12, 2024. REUTERS/Mina Kim
A person takes a photo of a new artwork by the British artist Banksy in Charlton, London, Britain, August 12, 2024. REUTERS/Mina Kim
TT
TT

Banksy Unveils New Rhino Art in London

A person takes a photo of a new artwork by the British artist Banksy in Charlton, London, Britain, August 12, 2024. REUTERS/Mina Kim
A person takes a photo of a new artwork by the British artist Banksy in Charlton, London, Britain, August 12, 2024. REUTERS/Mina Kim

Street artist Banksy on Monday unveiled a new mural of a rhinoceros that looks like it is climbing on top of a car in London — the eighth animal-themed artwork he has posted in the past week in a collection that includes elephants, a goat, a wolf, pelicans and more.

The elusive graffiti artist, who has never confirmed his full identity, has been posting the new work on his Instagram account every day since last Monday. The latest piece in Charlton, southeast London, features a rhino on a wall and gives the impression the animal is mounting a broken-down car parked in front of the building.

On Sunday, the artist claimed another artwork depicting piranhas which appeared on a police box near the Central Criminal Court, known as the Old Bailey, in London, The Associated Press reported.

A small crowd of people flocked to the fish tank-themed artwork Monday, taking photos and selfies as workmen placed barriers around it. A spokesman for the City of London Corporation said it was looking at options to preserve it.
Other pieces unveiled last week included pelicans that appeared on the side of a fish shop in Walthamstow, east London, and a silhouette of a howling wolf that was painted on a satellite dish on a garage roof in south London.

People gather to look at an artwork by Britain-based street artist Banksy on an old police sentry box in the City of London in London, Britain, 11 August 2024. EPA/ANDY RAIN

The wolf design was seen taken down by men who carried it off on the same day it was revealed. It is not immediately clear who removed the satellite dish.
Banksy began his career spray-painting buildings in Bristol, England, and has become one of the world’s best-known artists. His work has sold for millions of dollars at auction, and past murals on outdoor sites have often been stolen or removed by building owners soon after going up.

Most Viewed

 
 
Varieties

FDA Approves First Nasal Spray to Treat Dangerous Allergic Reactions

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, US, August 29, 2020. REUTERS/Andrew Kelly/File Photo Purchase Licensing Rights
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, US, August 29, 2020. REUTERS/Andrew Kelly/File Photo Purchase Licensing Rights
TT
TT

FDA Approves First Nasal Spray to Treat Dangerous Allergic Reactions

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, US, August 29, 2020. REUTERS/Andrew Kelly/File Photo Purchase Licensing Rights
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, US, August 29, 2020. REUTERS/Andrew Kelly/File Photo Purchase Licensing Rights

US health officials on Friday approved a nasal spray to treat severe allergic reactions, the first needle-free alternative to shots like EpiPen.

The Food and Drug Administration said it approved the spray from drugmaker ARS Pharmaceuticals Inc. as an emergency treatment for adults and older children experiencing life-threatening allergic reactions known as anaphylaxis, The AP reported.

Anaphylaxis occurs when the body's immune system develops a sudden, unexpected reaction to a foreign substance, such as food, insect stings or medications. Common symptoms include hives, swelling, itching, vomiting and difficulty breathing.

The device, marketed as Neffy, could upend treatment for the 33 million to 45 million Americans with severe allergies to food and other triggers. Anaphylaxis sends more than 30,000 people to emergency rooms and results in more than 2,000 hospitalizations and more than 230 deaths in the US each year.

Of the 6 million prescriptions written for auto-injectors each year, more than 40% are never filled, Dr. Thomas Casale, an allergist at the University of South Florida, told an FDA advisory panel last year. Even when they are available to caregivers, many auto-injectors are used incorrectly, he said.

“There’s a real unmet medical need for a large portion of the population,” he said.

Neffy is intended for people who weigh at least 66 pounds. It is given in a single dose sprayed into one nostril. A second dose can be given if the person’s symptoms don’t improve.

The new treatment could be life-changing for people with severe food allergies, said Dr. Kelly Cleary, a pediatrician and director with the Food Allergy Research & Education, a nonprofit advocacy group.

“I have seen the look of worry or fear,” said Cleary, whose 11-year-old son has multiple food allergies. “I worry about what happens if someone hesitates.”

Requiring an injection in an emergency is as scary to some children as the allergic reaction itself. Some parents have had to restrain thrashing children to inject them, sometimes causing cuts that require stitches. About 3,500 caregivers a year are injured when they accidentally inject themselves in the hands, ARS said.

Priscilla Hernandez, of Pasadena, California said her 12-year-old son, Zacky, who is allergic to sesame, peanuts, tree nuts, avocado and other foods, was traumatized when he had a reaction at school about six years ago and a nurse treated him with an auto-injector.

“Having to do a shot creates this whole different level of anxiety,” she said.

She said, “we are over the moon” about the FDA's approval of the spray, which Zacky will start carrying when it becomes available.

First marketed in 1901, epinephrine predates the FDA itself. Products like the EpiPen auto-injector, approved in 1987, were authorized based on chemistry and manufacturing data and were not required to prove safety and efficacy.

Clinical trials of people experiencing potentially deadly reactions are difficult for ethical and pragmatic reasons. Instead, ARS officials compared the effect of the nasal spray on biological markers to existing epinephrine treatments.

Results showed Neffy worked about as well as injected epinephrine to boost heart rate and blood pressure, which counter severe reactions. The drug is combined with a patented agent that allows it to be easily absorbed through nasal membranes.